178 related articles for article (PubMed ID: 3960418)
1. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
Fu YS; Ro J; Reagan JW; Hall TL; Berek J
Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
3. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome.
Demirel D; Laucirica R; Fishman A; Owens RG; Grey MM; Kaplan AL; Ramzy I
Cancer; 1996 Apr; 77(8):1494-500. PubMed ID: 8608534
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
5. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
6. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of DNA content and nuclear morphology in borderline ovarian tumors.
Drescher CW; Flint A; Hopkins MP; Roberts JA
Gynecol Oncol; 1993 Feb; 48(2):242-6. PubMed ID: 8428698
[TBL] [Abstract][Full Text] [Related]
9. The role of DNA flow cytometry in borderline malignant ovarian tumors.
Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM
Cancer; 1996 Aug; 78(4):794-802. PubMed ID: 8756374
[TBL] [Abstract][Full Text] [Related]
10. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: evidence for clonal evolution and invasive potential.
Crickard K; Marinello MJ; Crickard U; Satchidanand SK; Yoonessi M; Caglar H
Cancer Genet Cytogenet; 1986 Oct; 23(2):135-43. PubMed ID: 3756833
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
12. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
13. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
14. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
Liu C; Zhao Y; Sun X
Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
[TBL] [Abstract][Full Text] [Related]
15. Management of borderline tumors of the ovary: state of the art.
Tropé C; Kaern J
Semin Oncol; 1998 Jun; 25(3):372-80. PubMed ID: 9633850
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
17. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.
Kigawa J; Minagawa Y; Ishihara H; Kanamori Y; Terakawa N
Cancer; 1993 Aug; 72(3):804-8. PubMed ID: 8334634
[TBL] [Abstract][Full Text] [Related]
18. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
19. Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer.
Guidozzi F; Szumel RC; Ball JH; Johnston DA; Katz RL; Kidd L
Gynecol Oncol; 1996 May; 61(2):204-9. PubMed ID: 8626133
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
